Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma

Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.

Inclusion Criteria:

• Conformed diagnosis of follicular lymphoma, grades 1,2 or 3
• No prior chemotherapy
• No prior monoclonal antibody therapy
• Bulky or symptomatic disease, stage II-IV
• Performance status 0-2

Exclusion Criteria:

• Impaired bone marrow reserve
• Presence of CNS lymphoma
• Serious nonmalignant disease or active infection